title: Interleukin-2 gene has superior antinociceptive effects when delivered intrathecally.
abstract: The antinociceptive effect of interleukin-2 gene on rat carrageenan-induced pain was explored using different delivery methods. Intrathecal (i.t.) or plantar s.c. delivery of plasmid harbouring the interleukin-2 gene produced a marked antinociceptive effect, which was maintained up to 6 days; the administration of recombinant human interleukin-2 only had a transitory effect. The antinociceptive effect lasted longer and was more potent when the interleukin-2 gene was administered i.t. than when delivered s.c. The effect of the interleukin-2 gene was related to its protein expression, was dose dependent, and could be potentiated by liposome. The results suggest that the interleukin-2 gene has a good prospect for clinical use.
authors: Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 200031, PR China.
authors: Ming-Zhong
authors: MZ
authors: Yao
authors: Jin-Hui
authors: JH
authors: Wang
authors: Jin-Fa
authors: JF
authors: Gu
authors: Lan-Ying
authors: LY
authors: Sun
authors: Huan
authors: H
authors: Liu
authors: Zhi-Qi
authors: ZQ
authors: Zhao
authors: Xin-Yuan
authors: XY
authors: Liu
mesh_terms: D000344:Afferent Pathways / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D002411:Cation Exchange Resins / Q000494:pharmacology; D018076:DNA, Complementary / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D015870:Gene Expression / Q000502:physiology; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use; D007202:Indicators and Reagents / Q000494:pharmacology; D007278:Injections, Spinal / Q000379:methods; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000235:genetics* / Q000494:pharmacology; D008055:Lipids / Q000494:pharmacology; D008297:Male; D009619:Nociceptors / Q000187:drug effects* / Q000378:metabolism; D010146:Pain / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D010957:Plasmids / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D020671:Posterior Horn Cells / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D002411:Cation Exchange Resins; D018076:DNA, Complementary; D007202:Indicators and Reagents; D007376:Interleukin-2; D008055:Lipids; C086724:Lipofectamine